Using an unbiased high-content drug screen, we identified several small molecules that selectively inhibit LAPTM4B, and demonstrated that combination treatment with copanlisib and EGFR-TKIs produces robust anti-tumor effects in vitro and in vivo with negligible side effects. The gene discussed is EGFR; the disease is neoplasm.